AIM: To evaluate the outcome of transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma (HCC) <5 cm in diameter eligible for radiofrequency ablation (RFA). METHODS: The treatment-related mortality, morbidity, long-term survival, and prognostic factors of HCC patients who had TACE and fulfilled the present inclusion criteria for RFA were evaluated. RESULTS: Of the 748 patients treated with TACE between January 1990 and December 2002, 114 patients were also eligible for RFA. The treatment-related mortality and morbidity were 1% and 19%, respectively. Survival at 1, 3, and 5 years was 80%, 43%, and 23%, respectively. Older age and a high albumin level were associated with a better survival, whereas a high alpha-fetoprotein level (AFP) and the size of the largest tumor >3 cm in diameter were adverse prognostic factors in multivariate analysis. CONCLUSION: The morbidity, mortality, and survival data after TACE for small HCCs eligible for RFA are comparable to those reported after RFA in the literature. Our data suggest the need for a randomized comparison of the two treatment modalities for small HCCs.
AIM: To evaluate the outcome of transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma (HCC) <5 cm in diameter eligible for radiofrequency ablation (RFA). METHODS: The treatment-related mortality, morbidity, long-term survival, and prognostic factors of HCC patients who had TACE and fulfilled the present inclusion criteria for RFA were evaluated. RESULTS: Of the 748 patients treated with TACE between January 1990 and December 2002, 114 patients were also eligible for RFA. The treatment-related mortality and morbidity were 1% and 19%, respectively. Survival at 1, 3, and 5 years was 80%, 43%, and 23%, respectively. Older age and a high albumin level were associated with a better survival, whereas a high alpha-fetoprotein level (AFP) and the size of the largest tumor >3 cm in diameter were adverse prognostic factors in multivariate analysis. CONCLUSION: The morbidity, mortality, and survival data after TACE for small HCCs eligible for RFA are comparable to those reported after RFA in the literature. Our data suggest the need for a randomized comparison of the two treatment modalities for small HCCs.
Authors: Y Akashi; C Koreeda; S Enomoto; S Uchiyama; T Mizuno; Y Shiozaki; Y Sameshima; K Inoue Journal: Hepatology Date: 1991-08 Impact factor: 17.425
Authors: Roberto Miraglia; Giada Pietrosi; Luigi Maruzzelli; Ioannis Petridis; Settimo Caruso; Gianluca Marrone; Giuseppe Mamone; Giovanni Vizzini; Angelo Luca; Bruno Gridelli Journal: World J Gastroenterol Date: 2007-12-07 Impact factor: 5.742
Authors: Roberto Miraglia; Giada Pietrosi; Luigi Maruzzelli; Ioannis Petridis; Settimo Caruso; Gianluca Marrone; Giuseppe Mamone; Giovanni Vizzini; Angelo Luca; Bruno Gridelli Journal: World J Gastroenterol Date: 2007-06-07 Impact factor: 5.742
Authors: Suk Kyeong Ji; Yun Ku Cho; Yong Sik Ahn; Mi Young Kim; Yoon Ok Park; Jae Kyun Kim; Wan Tae Kim Journal: Korean J Radiol Date: 2008 Nov-Dec Impact factor: 3.500